129 related articles for article (PubMed ID: 38626490)
41. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
42. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
43. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA
Eur J Med Chem; 2019 May; 170():87-98. PubMed ID: 30878834
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
45. Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors.
Atta-Allah SR; AboulMagd AM; Farag PS
Bioorg Chem; 2021 Jul; 112():104923. PubMed ID: 33932767
[TBL] [Abstract][Full Text] [Related]
46. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
47. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
48. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.
Wang XR; Wang S; Li WB; Xu KY; Qiao XP; Jing XL; Wang ZX; Yang CJ; Chen SW
Eur J Med Chem; 2021 Mar; 213():113192. PubMed ID: 33493829
[TBL] [Abstract][Full Text] [Related]
52. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
53. Discovery of pyridine- sulfonamide hybrids as a new scaffold for the development of potential VEGFR-2 inhibitors and apoptosis inducers.
Ahmed MF; Santali EY
Bioorg Chem; 2021 Jun; 111():104842. PubMed ID: 33798847
[TBL] [Abstract][Full Text] [Related]
54. Novel Tetrahydrobenzo [b] Thiophene Compounds Exhibit Anticancer Activity through Enhancing Apoptosis and Inhibiting Tyrosine Kinase.
El-Metwally SA; Khalil AK; El-Naggar AM; El-Sayed WM
Anticancer Agents Med Chem; 2018; 18(12):1761-1769. PubMed ID: 30101717
[TBL] [Abstract][Full Text] [Related]
55. Synthesis of Tetrahydrobenzo[
Mohareb RM; Wardakhan WW; Abbas NS
Anticancer Agents Med Chem; 2019; 19(14):1737-1753. PubMed ID: 30947678
[TBL] [Abstract][Full Text] [Related]
56. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents.
Pathak A; Pandey V; Raj Pokharel Y; Devaraji V; Ali A; Haider K; Saad S; Dewangan RP; Siddiqui N; Shahar Yar M
Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents.
Ghith A; Youssef KM; Ismail NSM; Abouzid KAM
Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
59. Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation.
Rizk OH; Teleb M; Abu-Serie MM; Shaaban OG
Bioorg Chem; 2019 Nov; 92():103189. PubMed ID: 31473473
[TBL] [Abstract][Full Text] [Related]
60. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
